Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a highly drug-treated condition that uses an array of drug classes, including, but not limited to, selective serotonin reuptake inhibitors (SSRIs), selective serotonin and norepinephrine reuptake inhibitors (SNRIs), and—as adjunctive therapies—atypical antipsychotics. Although this drug market is ingrained with generic therapies, MDD patients’ heterogeneous response to current drugs and the need for additional efficacious therapies give branded agents (e.g., Trintellix [Lundbeck / Takeda], Rexulti [Otsuka / Lundbeck], Vraylar [AbbVie], Spravato [Johnson & Johnson Innovative Medicine], Auvelity [Axsome Therapeutics]) the opportunity to be incorporated into the treatment algorithm. Given MDD’s highly competitive landscape encompassing both long-established and newer-to-market drugs, it is valuable for drug marketers and developers to understand physicians’ actual prescribing behavior in MDD. Our Treatment Algorithms study provides national patient-level claims data to explore the use of key therapies in both newly diagnosed and recently treated patients, providing insight into the current MDD treatment landscape.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed MDD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed MDD patients?
- How have Trintellix, Rexulti, Vraylar, Spravato, and Auvelity been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of MDD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of MDD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Key drugs covered
Trintellix, Rexulti, Vraylar, Spravato, Auvelity, sertraline, escitalopram, bupropion SR/XL, duloxetine
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Key features
Dashboard featuring interactive visuals, easy navigation, and expanded analyses.
Real-world data
Longitudinal patient-level claims data analysis
Key analyses
- Brand / therapy usage across longitudinal patient sample
- Newly diagnosed patient analysis
- Treatment initiation and progression
- Line of therapy analysis
- Combination therapy analysis
- Source of business for recently treated patients
- Persistency and compliance analysis
- Product-level patient flow charts
